New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives!

Diabetes Dialogue: American Diabetes Association Trial Recap – Part 1

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, recap some of the biggest clinical trials presented at the 

The episode begins by addressing the Vertex study, highlighting data on VX-880, an allogeneic stem cell-derived islet cell therapy for 

. Of the 12 participants with impaired hypoglycemia awareness and a history of severe hypoglycemic events, 10 achieved insulin independence with over 90% time in range at 12 months. Although the therapy requires immunosuppression, the results mark a major step toward a functional cure, with larger trials ongoing.

Next, Isaacs and Bellini discuss the ADJUNCT T1D trial evaluating semaglutide 1 mg weekly in adults with type 1 diabetes and obesity on AID systems. Semaglutide led to significant A1c reductions (–0.7%), an 8.8% increase in time-in-range, 10% average body weight loss, and reduced total daily insulin doses—without increasing time below range. Notably, 36% of participants met the composite endpoint, compared to 0% on placebo, reinforcing the need for broader access to GLP-1 therapies in type 1 diabetes.

Isaacs and Bellini also review the phase 3 ACHIEVE-1 trial of orforglipron, a novel, oral non-peptide GLP-1 receptor agonist. Orforglipron demonstrated A1c reductions of up to 1.6%, 76% target attainment (<7% A1c), and 8% weight loss without the fasting or timing restrictions of existing oral options. The hosts highlight its ease of use and potential to improve adherence and expand treatment access.

The episode highlights and emphasizes the increasing momentum behind innovative therapies in type 1 and type 2 diabetes. The rapid advancements of the last year may be priming the endocrinology field for even more progress in the future. Isaacs and Bellini preview more pivotal data to be covered in part two.

Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

Podcasts

Isaacs and Bellini cover 3 of the most pivotal trial results from the 85th annual American Diabetes Association conference in part 1 of this 2-part recap.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Videos

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Type 2 Diabetes

Type 1 Diabetes

Credit: University of California, Riverside

At the 2025 Southern California Psychiatry (So Cal Psych) Conference from July 11 – 24 at Huntington Beach, California, Jerry McGuire, MD, director of the residency training and chair of psychiatry at the College Medical Center in Long Beach, California, presented on how to detect 

. It comes down to 1 thing: family history.

McGuire is also the founder and president of the Stuttering Treatment and Research Society (STARS), a non-profit organization that has raised over $10 million to help people who stutter and raise awareness for this neurological condition. In this interview, McGuire shared how to differentiate bipolar depression from MDD, causes and treatments for agitation, and how to treat anxiety or depression caused by stuttering.

: Today at the conference, you're talking about the difference between bipolar depression and MDD. Can you tell our audience how they tell the difference?

The key is cross-sectional. When you see someone and they're depressed, you can't tell necessarily. I wish in psychiatry we had blood tests or biomarkers, but [it] wouldn't be as much fun.

The best way we differentiate is by history, and sometimes not just from the patient, but from the family members or others around them. We look longitudinally back; if there's ever been a history of mania, then this depressive episode that we're looking at now would be a bipolar I depression. If there's history of only hypomanic episodes, and now we're looking at a depressive episode, then that would be bipolar 2 depression.

There are certainly other clues in our diagnostic schema. One, if a patient has had a… misadventure on an antidepressant, if they've been prescribed an antidepressant and they got worse, they got more agitated…that may be a clue that what you're dealing with is a bipolar depression. If there's a family history, unfortunately, of people passing from suicide, that may be a clue as well, and even sometimes coexistent substance use that patients with bipolar may, at times, self-medicate. It's important to look into these other co-existing factors that may give us clues that this is a bipolar depression, as opposed to a major depressive episode of major depressive disorder.

: Once you've made that determination, what kind of treatments are you going to consider?

We tailor our therapies based upon the diagnosis. One thing I've always tried to teach my residents, if your known treatments aren't working, is a diagnosis correct? Sometimes [after] 3 or 4 antidepressants… patients aren't responding, or they're getting worse. Is it really major depressive disorder? That's 1 clue.

Keep in mind that not many agents are approved for bipolar depression. Most of our agents that we talk about as mood stabilizers may be effective in preventing a manic episode or treating mania or mixed states. Our options are more limited when it comes to bipolar depression, and we do have some agents that are FDA-approved specifically for bipolar depression.

: You're also talking about agitation and dementia, which has been a big topic lately, right?

With agitation and dementia, our hands have been really tied as clinicians, because unfortunately, for years, patients [were] getting older, and we had nothing FDA approved to treat them. If anything, agents we were using were given a box warning not to use about the risk potentially of increased mortality, cerebrovascular adverse events with antipsychotic agents in patients with agitation associated with dementia.

Fortunately, we have one agent that is on label now, and that's been FDA approved for the treatment of patients with agitation associated with dementia due to Alzheimer's. It's nice to know that we have that option. Fortunately, it appears that we may have other options, BFD approved in the fairly recent future.

: Could there be something that's leading to the agitation? Has a patient, say, had a change in environment?

When we change the environment [of patients with dementia], they may become more restless, more agitated. Look for other things that could be leading to it. For instance, a co-morbid medical condition. Perhaps they have a urinary tract infection. Maybe this is a delirium, that there's some drug interaction [playing] a role. Maybe there's a slight infection, maybe there's a metabolic issue. So, before we go adding on another medicine, make sure that we know medically what's also going on for that patient. Make sure our patients are not in pain before we add something else [to the] board.

: What's the long-term prognosis and treatment strategy for someone with agitation dementia?

Right now, we have data that shows that we can treat this acutely. We do know that agitation, in and of itself, leads to a poor prognostic outcome for patients with dementia. We know our goal is to keep our patients in the least restrictive, most supportive environment we can. The longer we can keep them at home, surrounded [by] their family members, the better. The key is preventing those agitation episodes and treating them allows these individuals [to] have a better quality of life and to spend more time with their loved ones.

: For patients who come in and see a psychiatrist, maybe they are dealing with depression and anxiety as a result of their stuttering. What can psychiatrists do to help?

It's so important because [among] people [who stutter], over 80% may struggle with social anxiety. We also know that it's coexisting. Stuttering is a basal ganglia condition.

The key [is] to understand what treatments may make the underlying stuttering worse, and how best we can treat the underlying depression and anxiety, and attention issues. It's going to be a comprehensive approach, understanding we're developing, hopefully, newer treatments, that can help the core features of stuttering and then work toward cognitive behavioral and other forms of therapy, and even agents to treat the social anxiety or treat with the ADHD or the obsessive compulsive symptoms without worsening the underlying stuttering.

: Anything else that you want to talk about this, or anything else in psychiatry that you think is important for readers?

Well, I think what's important for individuals that psychiatry…is [often] misunderstood because we're dealing with really the most complex organ system, and that's the human brain. It's more difficult to understand than, say, the heart, the kidney.

As we learn more about neuroscience, the understanding will grow among healthcare professionals, and compassion will grow. We need better targeted treatments, and they're going to be personalized, not one size fits all, and so the diversity of what we see in psychiatric conditions will require that diverse treatment approach as well.

Articles

Differentiating bipolar depression from major depressive disorder (MDD) relies heavily on family history and longitudinal patient assessment. Misadventures with antidepressants and family history of suicide can indicate bipolar depression. Treatment options for bipolar depression are limited, with few FDA-approved agents. Agitation in dementia patients is challenging to manage, but recent FDA approvals offer new options. Environmental changes and co-morbid conditions can exacerbate agitation. For stuttering-related anxiety and depression, a comprehensive approach is essential, considering potential treatment impacts on stuttering. Psychiatry requires personalized, diverse treatment strategies due to the complexity of the brain.

At 2025 So Cal Psych, McGuire shared insights on diagnosing bipolar depression, treating agitation in dementia, and managing mental health challenges in patients who stutter.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Bipolar Disorder

The HCPLive bipolar disorder page is a resource for medical news and expert insights on BPD. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for bipolar disease, and more.

How Family History Distinguishes Bipolar Depression From MDD, With Jerry McGuire, MD

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

 infection entering opioid use disorder (OUD) treatment in the United States, female sex and recent pregnancy are independent risk factors for reduced likelihood of direct-acting antiviral (DAA) prescription, according to findings from a recent study.

Leveraging data from the Merative MarketScan Commercial and Multi-State Medicaid Databases, the study found significant differences in DAA prescription between men and women, most starkly in women with recent pregnancy compared to men and women without recent pregnancy. Given findings illustrating challenges in postpartum linkage to HCV care, investigators suggest pregnancy could be a window of opportunity for HCV treatment that merits further research.

“People with hepatitis C are often asymptomatic for years after being exposed, so if you are young, otherwise healthy and have a new baby, getting prompt treatment may not be a top priority, especially if it is challenging to access,” said first study author Caroline Cary, a third-year medical student at WashU Medicine.

 “It’s imperative to make hepatitis C care more readily accessible to new moms considering the long-term consequences of the condition.”

According to the World Health Organization, an estimated 50 million people have chronic HCV infection, with about 1 million new infections occurring per year. HCV is commonly transmitted via injecting drug use through the sharing of injection equipment, which has become especially pertinent during the ongoing opioid epidemic, as well as from an infected mother to her baby.

Notably, postpartum linkage to care has been poor, with one study finding just 6% of women with Medicaid insurance with OUD and HCV infection received DAAs within 6 months of delivery.

To contextualize emerging data and evaluate the association between pregnancy in the past year and prescription of DAAs, investigators conducted a retrospective cohort study of individuals with HCV infection entering OUD treatment using the Merative MarketScan Commercial and Multi-State Medicaid Databases. The outcome variable of interest was the prescription of DAAs after the initiation of OUD treatment, with 

 defined as receiving a first-time prescription of ≥ 1 DAA.

The exposure variables of interest were sex and recent pregnancy status. To identify women with a recent pregnancy, investigators evaluated the previous 360 days for pregnancy status as > 1 claim for any pregnancy-related condition regardless of whether it culminated in live birth.

In total, the analysis included 22,347 episodes spanning 19,668 people with HCV infection who were initiating OUD treatment. This included 8864 men (45.1%), 7567 women without recent pregnancy (38.5%), and 3237 women with recent pregnancy (16.5%). Most of the sample (90.8%) was enrolled in Medicaid, among whom the majority were non-Hispanic White (89.2%).

A total of 7332 individuals (37.3%) were prescribed DAAs within 1 year of OUD treatment. Investigators noted men were the most likely to be prescribed DAAs (40.6%), followed by women without recent pregnancy (35.7%) and women with recent pregnancy (31.8%).

In adjusted analyses, men and women without recent pregnancy had greater rates of HCV treatment compared with women with recent pregnancy (adjusted hazard ratio [aHR], 1.18; 95% CI, 1.13–1.24; and aHR, 1.09; 95% CI, 1.04–1.13, respectively).

“In summary, our findings identify recent pregnancy as a barrier to HCV treatment and possible driver in observed sex-based disparities. Further research must be done to determine optimal care delivery strategies for pregnant and postpartum individuals,” investigators concluded.

“Given the challenges described regarding postpartum linkage to HCV care, we suggest that pregnancy could be a window of opportunity for HCV treatment that must be further studied.”

Cary CB, McCrary ML, Marks LR, et al. Association Between Sex and Recent Pregnancy and Hepatitis C Virus Treatment in People With Opioid Use Disorder. O&G Open. 

Washington University in St. Louis. Hepatitis C Treatment Is Not Reaching Some at-Risk Populations. Newswise. July 14, 2025. Accessed July 15, 2025. 

https://www.newswise.com/articles/hepatitis-c-treatment-is-not-reaching-some-at-risk-populations/?sc=mwhr&xy=10023887

World Health Organization. Hepatitis C. April 9, 2024. Accessed July 15, 2025. 

https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

Jarlenski M, Chen Q, Ahrens KA, et al. Postpartum follow-up care for pregnant persons with opioid use disorder and hepatitis C virus infection. 

A recent study highlights that female sex and recent pregnancy are independent risk factors for reduced likelihood of direct-acting antiviral (DAA) prescription among individuals with hepatitis C virus (HCV) entering opioid use disorder (OUD) treatment. The study, using data from the Merative MarketScan databases, found significant disparities in DAA prescriptions, particularly among women with recent pregnancies. Despite the high prevalence of HCV, postpartum linkage to care remains poor. The study suggests that pregnancy could be a critical window for HCV treatment, warranting further research to optimize care delivery strategies for pregnant and postpartum individuals.

Female sex and recent pregnancy were independent risk factors for reduced likelihood of DAA prescription among people with HCV entering opioid use disorder treatment.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Female Sex, Recent Pregnancy Linked to Poor HCV Treatment Rates in Opioid Use Disorder

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

New findings suggest that while serum interleukin (IL)-13 levels are lower in patients with 

 compared to healthy controls, suggesting IL-13 maintains a complex role in disease pathogenesis, IL-13 levels do not correlate with bullous pemphigoid severity or prognosis.

Marwan Dawood, MD, from the Department of Dermatology at Rambam Health Care Campus in Israel, led a team of investigators who authored this analysis. Dawood et al highlighted that bullous pemphigoid is the most commonly seen autoimmune blistering disease, with prevalence that has reportedly risen in recent years.

“Our study aimed to compare IL-13 levels between DPP4-induced [bullous pemphigoid] and non-triggered [bullous pemphigoid], as well as to compare these levels with those of healthy controls and pemphigus patients,” Dawood and colleagues wrote.

The investigative team's retrospective cohort study involved an assessment of adult patients diagnosed with bullous pemphigoid between 2008 - 2023, specifically among those given a diagnosis at the dermatology department of Rambam Hospital in Haifa, Israel. Through a clinical evaluation alongside positive findings from direct immunofluorescence (DIF), specifically IgG deposition along the basement membrane, these diagnoses were confirmed. Those deemed as eligible participants were adults ≥18 years who also had a confirmed diagnosis shown to be supported by clinical, histopathological, and immunological evidence.

There were 12 healthy individuals and 4 patients with pemphigus vulgaris in the control arm of the analysis. Healthy controls were matched to subjects with bullous pemphigoid by sex and by age to diminish the possibility of demographic bias. Notably, the investigators found that none of those in the control arm had a personal history of autoimmune or inflammatory conditions. 

Serum samples, after being obtained from all study participants at the time of diagnosis, frozen prior to the initiation of any BP-specific treatment at −80°C until additional analyses were required. IL-13 levels were quantified by Dawood and colleagues via a commercially available IL-13 ELISA kit, with measurements being done at a single time point rather than throughout treatment.

The primary aim of Dewad and coauthors' assessment was to evaluate serum IL-13 concentrations and their relationship with etiology of bullous pemphigoid, with peripheral eosinophil counts, with the requirements for adjunctive treatment, and with mucosal involvement. Using electronic medical records, they collected clinical and laboratory data such as demographic characteristics, disease origin, treatment information, and results of patients' blood tests.

Overall, the investigators concluded that mean serum IL-13 levels were significantly lower among those with bullous pemphigoid (n=42; mean 62.46 pg/mL ± 16.53) compared to healthy controls (n=12; mean 87.83 pg/mL ± 8.87, 

 < .0001) and compared to those with pemphigus vulgaris (n=4; mean 87.6 pg/mL ± 5.16, 

 Within the bullous pemphigoid subgroup, it was noted that subjects with idiopathic bullous pemphigoid showed higher IL-13 levels versus those with DPP4-inhibitor–associated bullous pemphigoid (67.01 pg/mL ± 14.3 versus 57.36 pg/mL ± 21, 

The team did not observe any statistically significant associations between IL-13 levels and eosinophil counts (Pearson’s r = .18, 

 = .338), utilization of adjuvant therapy (

 = .32), or patients' disease prognosis (

 = .45). However, they did find a significant link between elevated eosinophil counts and the need for adjuvant treatment (

“This study highlights the significant variability in serum IL-13 levels among [bullous pemphigoid] patients, distinguishing idiopathic and DPP4i-induced [bullous pemphigoid],” the team concluded.

 “...With the emergence of anti-IL13 biologics, our findings emphasize the need for further research into IL-13's role in [bullous pemphigoid] pathogenesis and treatment, towards the development of future personalized approaches in [bullous pemphigoid] management.”

RL Colbert, DM Allen, D Eastwood, et al. “Mortality Rate of Bullous Pemphigoid in a US Medical Center,” Journal of Investigative Dermatology 122, no. 5 (2004): 1091–1095, 

https://doi.org/10.1111/j.0022-202X.2004.22504.x

Dawood M, Saleh ZA, Boyango I, et al. The Complex Role of IL-13 in Bullous Pemphigoid: New Insights From a Retrospective Cohort Study. JEADV Clinical Practice. 

Serum interleukin (IL)-13 levels are lower in bullous pemphigoid (BP) patients compared to healthy controls, but do not correlate with disease severity or prognosis. A retrospective cohort study led by Marwan Dawood, MD, analyzed IL-13 levels in BP patients, including those with DPP4-inhibitor–associated BP, and compared them to healthy controls and pemphigus vulgaris patients. The study found significant variability in IL-13 levels among BP patients, highlighting the need for further research into IL-13's role in BP pathogenesis and treatment.

This analysis suggests serum IL-13 levels are lower in bullous pemphigoid patients than in healthy controls and pemphigus vulgaris patients.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Study Highlights Complex Role of IL-13 Among Patients with Bullous Pemphigoid

New research is shedding light on a high prevalence of sarcopenia among patients with 

 receiving dialysis, especially those on hemodialysis.

The systematic review included 62 studies with > 15,000 participants and determined the global prevalence of sarcopenia to be 30.1% for hemodialysis and 20.5% for peritoneal dialysis. Investigators additionally noted differences in prevalence based on which criteria was used and the timing of lean muscle mass (LMM) measurement.

Defined as the gradual loss of muscle mass, strength, and function, sarcopenia commonly affects the elderly population and is widely attributed to aging. However, chronic diseases like 

, cancer, and HIV have also been identified as potential causes and exacerbating factors of sarcopenia.

“Although several studies have reported the prevalence of sarcopenia in the CKD and dialysis population, there remains a significant lack of quantitative syntheses focusing on dialysis modality assessment criteria, timing of assessment, and the tools used for measuring muscle mass,” Ritin Fernandez, a professor at the University of Newcastle and assistant dean (International) at the College of Health, Medicine, and Wellbeing, and colleagues wrote.

 “This gap limits the ability to draw meaningful comparisons and inform clinical practice.”

To address this gap in research, investigators systematically searched Ovid MEDLINE, Embase, Allied and Complementary Medicine Database, CINAHL, and Scopus electronic databases for studies assessing sarcopenia in adults ≥ 18 years of age with CKD undergoing dialysis.

Investigators retrieved an initial 174 articles, 62 of which met the inclusion criteria. These studies involved 15,382 participants (ranging from 20 to 3196 in each study), the majority of whom were receiving hemodialysis treatment (92%). All studies were published in the last 10 years, predominately in China (22%), Japan (19%), Korea (8%), and Taiwan (6%).

Results showed the global prevalence of sarcopenia was 30.1% (95% CIm 25.6%–39.9%; 

2: 97.1%) among people receiving hemodialysis and 20.5% (95% CI, 15.1–26.4%; 

2: 80.0%) among people receiving peritoneal dialysis. Investigators noted sarcopenia prevalence ranged from 23.1%-30.3% in hemodialysis and from 6.1%-26.9% in peritoneal dialysis based on the assessment criteria used.

To assess the effect of the timing of LMM assessment, investigators categorized studies using bioimpedance analysis (BIA) or bioimpedance spectroscopy (BIS) into pre- and post-dialysis. A total of 10 studies (n = 5177) investigated the LMM pre-dialysis with a sarcopenia prevalence of 24.2% (CI, 14.8%–35%; 

2: 97.8%). When the same instrument was used post-dialysis (14 studies, 

 = 3502), the prevalence of sarcopenia was 33% (CI, 24.7%–41.7%; 

Further analysis revealed measuring muscle mass after dialysis using dual-energy X-ray assessment yielded a lower prevalence of sarcopenia (22.5%; CI, 12.9–33.8; 

2: 93.3%) than BIA/BIS (33%; CI, 24.7–41.7; 

Investigators identified age, sex, diabetes, inflammation markers, nutritional indices, and dialysis vintage as risk factors for sarcopenia in the hemodialysis population but called attention to high heterogeneity between studies.

“There is a need for additional research to assess the practicality of various assessment tools and the role of other measurements or predictors of low muscle mass, strength, and sarcopenia,” investigators concluded.

 “Global research would benefit from the development of a single criterion to be applied to dialysis patients and standardize screening tools for this population.”

Stockings J, Heaney S, Chu G, et al. Prevalence and Risk Factors of Sarcopenia in People Receiving Dialysis: A Systematic Review and Meta-Analysis. 

Cleveland Clinic. Sarcopenia. June 3, 2022. Accessed July 15, 2025. 

https://my.clevelandclinic.org/health/diseases/23167-sarcopenia

Sarcopenia, characterized by the loss of muscle mass, strength, and function, is prevalent among chronic kidney disease (CKD) patients undergoing dialysis, particularly hemodialysis. A systematic review of 62 studies involving over 15,000 participants found a global sarcopenia prevalence of 30.1% in hemodialysis and 20.5% in peritoneal dialysis. Variability in prevalence was noted based on assessment criteria and timing of lean muscle mass measurement. The study highlights the need for standardized assessment tools and criteria to improve clinical practice and research in this population.

Sarcopenia was most prevalent among those on hemodialysis, but prevalence varied based on assessment criteria and timing of lean muscle mass measurement.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Sarcopenia Highly Prevalent Among Dialysis Patients, Study Finds

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

A study reveals a significant link between poor oral health and increased migraines and body pain in women, highlighting implications for fibromyalgia management.

Fibromyalgia

On the HCPLive fibromyalgia page, resources on the topics of medical news and expert insight into fibrositis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on fibromyalgia, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Oral Health and Body Pain, Migraines Significantly Correlated in Women

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Daily intake of baked milk significantly improved tolerance and immune markers in young children with baked milk tolerance, according to a 12-month study.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Early Baked Milk Introduction Speeds Cow’s Milk Allergy Resolution in Children

Professor of nursing at University of Alabama Huntsville and nurse practitioner and transplant coordinator at Vanderbilt University.

Explore how advanced practice practitioners enhance COPD care through innovative models, improving patient outcomes and addressing rural healthcare challenges.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Examining APP-Led Endobronchial Valve Therapy for COPD, with Haley Hoy, PhD, CRNP

This review provides guidance to clinicians in choosing effective and safe alopecia therapies during breastfeeding periods.

Alopecia

Safety Considerations Highlighted for Alopecia Treatments During Breastfeeding

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Already approved by the FDA based on data from the first half of the PaTHway trial, 3-year extended results have indicated lasting efficacy.

Thyroid Disorders

Palopegteriparatide Provides Sustained Response in Adults with Hypoparathyroidism

Hosts Kimberly Brown and Nancy Reau discuss policy, clinical, and structural milestones enabling HCV elimination efforts and critical gaps impeding progress.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Liver Lineup: Progress, Policy, and Barriers in Hepatitis C Elimination

Jonathan Meyer, MD, is a clinical professor of Psychiatry at UC San Diego and nationally recognized psychopharmacology educator.

Discover the latest insights on tardive dyskinesia treatment, diagnosis, and the role of VMAT2 inhibitors in enhancing patient well-being.

What’s New in Tardive Dyskinesia, With Jonathan Meyer, MD

Auchus discusses his recent presentation on the CATALYST trial, investigating the characteristics of patients with difficult-to-treat T2D because of hypercortisolism.

Hypercortisolism in Patients with Treatment-Resistant Type 2 Diabetes, with Richard Auchus, MD, PhD

A panelist discusses how indolent systemic mastocytosis presents with chronic, mast cell–mediated symptoms that significantly reduce quality of life, often persist despite treatment, and may lead to serious complications like anaphylaxis and osteoporosis.

Video Series

Understanding Indolent Systemic Mastocytosis (ISM): Symptoms and Impact

The previously approved technology has already accomplished over 10,000 procedures for patients with various heart diseases, primarily including atrial fibrillation.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Latest News

Diabetes Dialogue: American Diabetes Association Trial Recap – Part 1

How Family History Distinguishes Bipolar Depression From MDD, With Jerry McGuire, MD

Female Sex, Recent Pregnancy Linked to Poor HCV Treatment Rates in Opioid Use Disorder

Study Highlights Complex Role of IL-13 Among Patients with Bullous Pemphigoid

Sarcopenia Highly Prevalent Among Dialysis Patients, Study Finds